1. Home
  2. TGLS vs PHVS Comparison

TGLS vs PHVS Comparison

Compare TGLS & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tecnoglass Inc.

TGLS

Tecnoglass Inc.

HOLD

Current Price

$45.66

Market Cap

2.0B

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$34.81

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGLS
PHVS
Founded
1984
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.4B
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
TGLS
PHVS
Price
$45.66
$34.81
Analyst Decision
Strong Buy
Buy
Analyst Count
3
11
Target Price
$63.33
$41.82
AVG Volume (30 Days)
268.5K
566.0K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
1.41%
N/A
EPS Growth
N/A
N/A
EPS
0.71
N/A
Revenue
$370,984,000.00
N/A
Revenue This Year
$13.56
N/A
Revenue Next Year
$9.04
N/A
P/E Ratio
$66.25
N/A
Revenue Growth
17.98
N/A
52 Week Low
$37.52
$19.12
52 Week High
$83.32
$36.60

Technical Indicators

Market Signals
Indicator
TGLS
PHVS
Relative Strength Index (RSI) 56.63 57.18
Support Level $40.88 $24.73
Resistance Level $46.65 $36.60
Average True Range (ATR) 1.90 1.64
MACD 0.08 -0.14
Stochastic Oscillator 60.23 54.17

Price Performance

Historical Comparison
TGLS
PHVS

About TGLS Tecnoglass Inc.

Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: